Arthritis Pain Treatment

CEL-SCI's Rheumatoid Arthritis Vaccine Benefits Last Long

ruzik_tuzik — Fri, 14 Nov 2008 23:23:52 -0600

CEL-SCI Corporation presented new rheumatoid arthritis data at the 6th annual GTCbio Vaccine Conference in Vienna, Va. The data, presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology of CEL-SCI, indicate that CEL-SCI's rheumatoid arthritis treatment vaccine CEL-2000 prevents or retards the permanent tissue damage caused by rheumatoid arthritis. The long term results obtained with CEL-2000 vaccine, for the rheumatoid arthritis, were in line with those seen with Enbrel, a leading treatment for people with rheumatoid arthritis.

Antiangiogenic Role Of 2ME2 Demonstrated In Rheumatoid Arthritis Models

ruzik_tuzik — Mon, 03 Nov 2008 22:41:31 -0600

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem or 2-methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School of Medicine at UCLA, were published in the November 2008 issue of the Journal of Rheumatology (Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, and Plum SM.

ACTEMRA Inhibited Progression Of Joint Damage In RA Patients Demonstrated

ruzik_tuzik — Wed, 29 Oct 2008 06:40:19 -0500

One-year data from a two-year Phase III study demonstrated that ACTEMRA (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel interleukin-6 (IL-6) receptor inhibitor, in patients with moderately to severely active RA, will also be presented during the meeting.

ACTEMRA Significantly Reduced Signs, Symptoms Of Rheumatoid Arthritis

ruzik_tuzik — Mon, 27 Oct 2008 23:49:28 -0500

Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs and symptoms when treated with ACTEMRA (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone.

Discovery Yields Potential Gout Treatment

ruzik_tuzik — Mon, 27 Oct 2008 12:41:53 -0500

A new approach to treating gout -- a debilitating form of arthritis -- can normalize levels of uric acid in the blood within hours in patients who have failed to respond to any other treatments, and in some patients, eliminate the painful, needle-like crystals of uric acid that clump around fingers, toes and other joints.

Details of the use of the drug, pegloticase, among 212 patients with severe gout enrolled in two, phase III clinical trials, were released today at the annual meeting of the American College of Rheumatology.

Mayo Research Says Rheumatoid Arthritis Rising Among Women

hareyan — Mon, 27 Oct 2008 04:37:02 -0500

After four decades on the decline, rheumatoid arthritis is on the upswing among women in the United States. That's the finding presented by Mayo Clinic investigators at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals in San Francisco.

"This is a significant finding and an indicator that more research needs to be done to better understand the causes and treatment of this devastating disease," says Sherine Gabriel, M.D., Mayo Clinic rheumatologist and lead investigator on the study.

Treatment of psoriatic arthritis gets international guidelines

hareyan — Mon, 27 Oct 2008 04:17:59 -0500

Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.

New osteoarthritis study shows: most treatments don't work

hareyan — Thu, 23 Oct 2008 13:27:32 -0500

Meta-analysis calls into question the premises underlying classic osteoarthritis treatment guidelines.

Berlin, October 23, 2008. Despite the billions of euros spent on osteoarthritis treatments in Germany, the effectiveness of those treatments remains highly controversial among experts. According to the findings of a large-scale study presented today by Carsten Moser and Peter Wehling of Düsseldorf at the Orthopedics and Trauma Surgery Congress in Berlin, the largest German orthopedics conference, some therapies have now been shown to be ineffective while others are downright risky.

UK Researchers Scanning Arthritis Study

ruzik_tuzik — Wed, 08 Oct 2008 02:23:04 -0500

Leeds researchers are among the first in the country to use new state-of-the art imaging equipment in a bid to improve the diagnosis and monitoring of patients with a common form of inflammatory arthritis.

A team from the Leeds Institute of Molecular Medicine at the University of Leeds hope to demonstrate the effectiveness of two novel imaging techniques using a specially adapted MRI scanner.

Six New Genetic Indicators For Rheumatoid Arthritis

ruzik_tuzik — Wed, 08 Oct 2008 02:14:56 -0500

Researchers from Brigham and Women's Hospital (BWH) and colleagues have uncovered specific locations on chromosomes (loci) linked to rheumatoid arthritis (RA), a progressive autoimmune disease that attacks the joints and other organs. Variations in the genetic sequence at these locations imply a risk of developing RA.